DE60320816D1 - Pharmazeutische zusammensetzungen mit einem hiv-hüllprotein und cd4 - Google Patents
Pharmazeutische zusammensetzungen mit einem hiv-hüllprotein und cd4Info
- Publication number
- DE60320816D1 DE60320816D1 DE60320816T DE60320816T DE60320816D1 DE 60320816 D1 DE60320816 D1 DE 60320816D1 DE 60320816 T DE60320816 T DE 60320816T DE 60320816 T DE60320816 T DE 60320816T DE 60320816 D1 DE60320816 D1 DE 60320816D1
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- protein
- hiv envelope
- envelope protein
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 abstract 5
- 101710091045 Envelope protein Proteins 0.000 abstract 5
- 101710188315 Protein X Proteins 0.000 abstract 5
- 108010041397 CD4 Antigens Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 abstract 2
- 238000009169 immunotherapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0218817.5A GB0218817D0 (en) | 2002-08-13 | 2002-08-13 | Pharmaceutical compounds |
PCT/IB2003/003665 WO2004014420A1 (en) | 2002-08-13 | 2003-08-12 | Pharmaceutical compositions comprising an hiv envelope protein and cd4 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60320816D1 true DE60320816D1 (de) | 2008-06-19 |
Family
ID=9942235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60320816T Expired - Lifetime DE60320816D1 (de) | 2002-08-13 | 2003-08-12 | Pharmazeutische zusammensetzungen mit einem hiv-hüllprotein und cd4 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060142219A1 (de) |
EP (1) | EP1545602B1 (de) |
AT (1) | ATE394116T1 (de) |
AU (1) | AU2003253187A1 (de) |
CA (1) | CA2497662A1 (de) |
DE (1) | DE60320816D1 (de) |
GB (1) | GB0218817D0 (de) |
WO (1) | WO2004014420A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040076636A1 (en) * | 1993-05-07 | 2004-04-22 | Ranajit Pal | HIV immunogenic complexes |
MXPA04010919A (es) | 2002-05-07 | 2005-01-25 | Chiron Corp | Complejos e hibridos de envoltura de vih-cd4. |
US8206720B2 (en) | 2004-06-08 | 2012-06-26 | Novartis Vaccines & Diagnostics, Inc | Fusion proteins comprising CD4 minimal modules and invasin polypeptides that are capable of binding to the HIV envelope and exposing cryptic neutraliziation epitopes |
EP1893650B1 (de) * | 2005-02-03 | 2010-06-23 | Novartis Vaccines and Diagnostics, Inc. | Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür |
JP2013528370A (ja) * | 2010-05-07 | 2013-07-11 | デューク ユニバーシティー | Hiv−1サブタイプcエンベロープ糖タンパク質における遺伝子シグネチャー |
WO2014042669A1 (en) * | 2012-09-12 | 2014-03-20 | Duke University | Antibody evolution immunogens |
WO2016049633A1 (en) * | 2014-09-28 | 2016-03-31 | Duke University | Compositions and methods for transient immune response modulation during vaccination |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002337885B1 (en) * | 2001-10-16 | 2003-04-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes |
-
2002
- 2002-08-13 GB GBGB0218817.5A patent/GB0218817D0/en not_active Ceased
-
2003
- 2003-08-12 US US10/524,549 patent/US20060142219A1/en not_active Abandoned
- 2003-08-12 AT AT03784418T patent/ATE394116T1/de not_active IP Right Cessation
- 2003-08-12 CA CA002497662A patent/CA2497662A1/en not_active Abandoned
- 2003-08-12 WO PCT/IB2003/003665 patent/WO2004014420A1/en active IP Right Grant
- 2003-08-12 DE DE60320816T patent/DE60320816D1/de not_active Expired - Lifetime
- 2003-08-12 AU AU2003253187A patent/AU2003253187A1/en not_active Abandoned
- 2003-08-12 EP EP03784418A patent/EP1545602B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
GB0218817D0 (en) | 2002-09-18 |
ATE394116T1 (de) | 2008-05-15 |
AU2003253187A1 (en) | 2004-02-25 |
EP1545602A1 (de) | 2005-06-29 |
US20060142219A1 (en) | 2006-06-29 |
CA2497662A1 (en) | 2004-02-19 |
WO2004014420A1 (en) | 2004-02-19 |
EP1545602B1 (de) | 2008-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005035572A3 (en) | Antibody compositions and methods | |
DE60237704D1 (de) | Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden | |
EA200301159A1 (ru) | Цитотоксические иммуноконъюгаты антитела к cd44 | |
CY1118211T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν ενωσεις λανθανιου | |
UA93488C2 (uk) | Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг | |
ES8405071A1 (es) | Un procedimiento de preparacion de conjugados inmunoenzimaticos. | |
MXPA03009924A (es) | Anticuerpo recombinante especifico de tumor y uso del mismo. | |
EA200800696A1 (ru) | Полипептиды и антитела | |
ATE175446T1 (de) | Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung | |
ATE16683T1 (de) | Verwendung eines copolymeren aus acrylsaeure und maleinsaeure als anmischkomponente fuer glasionomerzemente. | |
YU127390A (sh) | Nova antitela reaktivna sa humanim karcinomima | |
MX2022008582A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
HRP20070198B1 (hr) | Smjese estrogen-ciklodekstrin kompleksa | |
BRPI0309868B8 (pt) | métodos de preparação de uma composição de reduzida fração conjugada inferior | |
AU7485301A (en) | Methods for refolding proteins containing free cysteine residues | |
TW200619217A (en) | Chemical compounds | |
DE60140458D1 (de) | Erhöhte in vitro-synthese von aktiven, disulfidbrücken-enthaltenden proteinen | |
ATE394116T1 (de) | Pharmazeutische zusammensetzungen mit einem hiv- hüllprotein und cd4 | |
ATE406385T1 (de) | Verkürztes cd200 | |
ATE326985T1 (de) | Lyophilisierte pharmazeutische zusammensetzung von propofol | |
TR200102877T2 (tr) | İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar. | |
ATE202485T1 (de) | Neue protein-polykation-konjugate | |
WO2000001820A3 (en) | Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof | |
DE60109922D1 (de) | Therapeutische verbindungen gegen eierstockkrebs | |
WO2023196947A3 (en) | Methods for activation and expansion of engineered natural killer cells and combinations with antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |